CliffBio
small molecule

TYKERB

LAPATINIB DITOSYLATE

Loss of exclusivitySeptember 2029latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameTYKERB
Active ingredientLAPATINIB DITOSYLATE
StrengthEQ 250MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2007
Marketing statusRX

Listed patents

PatentExpiresType
8821927September 2029substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TYKERB patent cliff — loss of exclusivity September 2029 | CliffBio